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Bilaterality of breast cancer is an indicator of constitutional cancer susceptibility; however, the molecular
causes underlying this predisposition in the majority of cases is not known. We hypothesize that epigenetic
misregulation of cancer-related genes could partially account for this predisposition. We have performed
methylation microarray analysis of peripheral blood DNA from 14 women with bilateral breast cancer com-
pared with 14 unaffected matched controls throughout 17 candidate breast cancer susceptibility genes
including BRCA1, BRCA2, CHEK2, ATM, ESR1, SFN, CDKN2A, TP53, GSTP1, CDH1, CDH13, HIC1, PGR,
SFRP1, MLH1, RARB and HSD17B4. We show that the majority of methylation variability is associated with
intragenic repetitive elements. Detailed validation of the tiled region around ATM was performed by bisulphite
modiﬁcation and pyrosequencing of the same samples and in a second set of peripheral blood DNA from 190
bilateral breast cancer patients compared with 190 controls. We show signiﬁcant hypermethylation of one
intragenic repetitive element in breast cancer cases compared with controls (P 5 0.0017), with the highest
quartile of methylation associated with a 3-fold increased risk of breast cancer (OR 3.20, 95% CI 1.78–5.86,
P 5 0.000083). Increased methylation of this locus is associated with lower steady-state ATM mRNA level
and correlates with age of cancer patients but not controls, suggesting a combined age–phenotype-related
association. This research demonstrates the potential for gene-body epigenetic misregulation of ATM and
other cancer-related genes in peripheral blood DNA that may be useful as a novel marker to estimate
breast cancer risk.
Accession numbers: The microarray data and associated .BED and .WIG ﬁles can be accessed through Gene
Expression Omnibus accession number: GSE14603.
INTRODUCTION
Breast cancer is one of the most common cancers in the
Western world affecting one in 10 women during their lifetime
(1). Mutations in the breast cancer susceptibility genes,
BRCA1 and BRCA2, and, to a lesser extent, CHEK2, TP53
and ATM, account for 25% of familial breast tumours (2).
The remaining 75% of familial breast cancers (BRCAx
tumours) and the majority of sporadic tumours are not attribu-
table to known mutations in any of these genes. In bilateral
cases of breast cancer (a second primary tumour in the
contra-lateral breast), it is believed that the underlying
‘mutation’ is not limited to the epithelial cells of one breast,
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Advance Access published on January 19, 2009but rather is systemic (3). The importance of epigenetic
changes in cancer development is now well established;
however, the role of epigenetic changes as a mechanism for
increased cancer risk is yet to be fully explored. Therefore,
we hypothesized that some of the systemic epigenetic
changes are either inherited or acquired in the early develop-
mental stages and therefore should be detectable in the
tissues other than breast, such as peripheral blood DNA
(4,5). Since carcinogenesis induces numerous genetic and epi-
genetic changes, the study of tumour cells alone cannot dis-
tinguish whether epigenetic inactivation of tumour
suppressor genes is a cause or a consequence of the neoplastic
process in breast cancer (6). Identiﬁcation of epimutations in
the tissues and cells that are not affected by the disease
process would favour causal association. Therefore, we
aimed to identify epigenetic misregulation of candidate
genes in the normal peripheral blood cells of cancer patients
compared with controls.
Epigenetics is the investigation of ‘any information that is
carried by the genome that is not coded by DNA’ and includes
DNA methylation, histone modiﬁcations, chromatin structure
and non-coding RNA-mediated regulation of gene expression
and various other genomic functions (7). DNA methylation
studies in cancer revealed two main types of changes: hyper-
methylation of promoter CpG islands and hypomethylation
of repetitive DNA sequences (8). DNA methylation is
heritable through mitosis and is copied to the new strand
by DNA methylatransferase 1 during DNA replication.
Meiotic heritability of DNA methylation states, particularly
transposon-associated methylation, has been shown in
mice and in plants; however, it is not yet clear whether
DNA methylation is heritable through meiosis in humans
(9,10). Recent evidence suggests that epimutations are likely
to arise somatically (11). Apart from trans-generational
inheritance of epigenetic states, single-generation germline
epigenetic effects are also possible. During germ cell develop-
ment, the epigenome is reprogrammed with two waves of
demethylation and re-establishment of DNA methylation
marks allowing the possibility of errors that could persist in
the germline (12). We have previously shown that the male
germline exhibits locus-, cell- and age-dependent DNA
methylation differences and that DNA methylation variation
is signiﬁcant across unrelated individuals, at a level that, by
far, exceeds DNA sequence variation (13). This has allowed
us to hypothesize that epigenetic variation in normal somatic
cells, which need not be transgenerational, could be a predis-
posing factor for cancer.
DNA methylation alterations have been studied extensively
in breast tumour tissues most recently with genome wide ana-
lyses revealing hypermethylated as well as hypomethylated
loci compared with matched adjacent tissues (14). Approxi-
mately 100 candidate genes have been reported throughout
the literature as promoters hypermethylated at varying fre-
quencies in breast cancers (Pubmeth http://matrix.ugent.be/
pubmeth/search.html). For our study, we have selected genes
that have either previously been identiﬁed as breast cancer sus-
ceptibility genes with known mutations in familial cases
(BRCA1, BRCA2, ATM, CHEK2, TP53) or genes that are fre-
quently hypermethylated in sporadic breast cancers (ESR1,
SFN, CDKN2A, GSTP1, CDH1, CDH13, HIC1, PGR,
SFRP1, MLH1, RARB and HSD17B4). We have used a two-
stage design to ﬁrstly identify methylation variable positions
(MVPs) in peripheral blood DNA and then secondly to test
selected sites for an association with breast cancer in a
larger sample set.
RESULTS
Microarray analysis
We performed differential DNA methylation analysis using a
methylation-sensitive enzyme-based approach to compare
the methylation status of peripheral blood DNA of 14 bilateral
breast cancer cases with 14 matched controls. We have
designed a custom-tiled microarray covering a total of 4 Mb
to completely cover 17 breast cancer susceptibility genes
(Supplementary Material, Fig. S1A) and an additional 34
genes also captured in the ﬂanking regions (Supplementary
Material, Table S1). Using the Model-based Analysis of
2-Color Arrays (MA2C) algorithm, we were able to detect
181 signiﬁcantly variable regions (P , 0.001) across the 28
individuals, which we have termed inter-individual MVPs.
These included 143 intragenic, or gene-body, MVPs and 38
intergenic regions not associated with known gene promoters
(Supplementary Material, Table S2). We observed intragenic
methylation variability in each of the remaining targeted
genes ATM, PGR, CDH1, CDH13, CHEK2, MLH1, RARB,
HSD17B4, ESR1, SFRP1 and CDKN2A. Of all of the genes
tested, we detected no signiﬁcant intragenic methylation varia-
bility in six of the targeted genes including BRCA1, BRCA2,
TP53, SFN, HIC1 and GSTP1 (Supplementary Material,
Fig. S2).
Methylation variability is located in intragenic
repetitive elements
Although the repetitive sequences themselves are not tiled, the
enrichment of unmethylated genome can assess methylation
status of the repetitive sequences by probing the unique
sequences ﬂanking the repeats (gaps in the tiling microarrays)
(Supplementary Material, Fig. S1B). To conﬁrm the associ-
ation of MVPs with repetitive elements, we have calculated
the distance from the middle of each peak to the nearest repeti-
tive element for each of the 181 identiﬁed loci. This analysis
identiﬁed 80/181 (44%) of MVPs within 100 bp of the
nearest repetitive element and 60% within 200 bp. This distri-
bution is signiﬁcantly closer to repetitive elements than can be
expected by random chance (P ¼ 7.39e–07, Kolmogorov–
Smirnov test) (Fig. 1A). The distribution of repeat element
type is not signiﬁcantly different to the distribution throughout
the genome. By aligning each gene at the transcription start
sites (TSSs) and averaging the MATScores, we were able to
generate a general picture of methylation variability over the
ﬁrst 10 kb of genes longer than 10 kb or across the ﬁrst 5 kb
of shorter genes. This reveals very low methylation variability
over all gene promoters up to the TSS and a sharp increase in
variability over the ﬁrst 1 kb of intragenic sequence followed
by periodic increase and decrease in variability every 2 kb
(Fig. 1B).
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We have performed a detailed validation of the MVPs within
the targeted region surrounding one gene, ATM, which we
have selected because it is known to contain germline
mutations in familial breast cancer cases with a clear patho-
genic role and it contains several intragenic MVPs associated
with repetitive elements (Fig. 2A). We used bisulphite modi-
ﬁcation coupled with pyrosequencing assays to map methyl-
ated cytosines in the repetitive elements nearest to six MVPs
in the targeted region surrounding ATM. We ﬁrst analysed
the 14 matched case–control paired samples that we per-
formed the microarray analysis on. Pair-wise comparison
of methylation percentages conﬁrmed the signiﬁcant
inter-individual variability in each of the loci identiﬁed by
the microarray as exempliﬁed by ATMmvp2a with 8/14
pairs signiﬁcantly different (P , 0.05, Wilcoxon signed rank
sum test) (Fig. 2B). Combined data from all of the 14 cases
and controls revealed no statistically signiﬁcant differences
overall between patients and controls; however, the highest
range of methylation across individuals were observed in the
intragenic regions nearest the TSSs. The two most variable
loci, ATMmvp1 and ATMmvp2, are both 4 kb downstream
of the start sites of the genes NPAT and ATM, respectively
(Fig. 2C). We detected no signiﬁcant difference in genome-
wide methylation as assessed by the pyrosequencing assay
for LINE1; therefore, any differences detected are unlikely
to be due to overall genome-wide methylation differences.
Furthermore, in each of the 14 cases and controls, we detected
no methylation of the ATM promoter CpG island in the peri-
pheral blood DNA.
We performed a second stage of validation for the most
variable loci, MVP2, within the ATM gene as well as the
ATM CpG island and LINE1 assays in peripheral blood
DNA from 190 bilateral breast cancer patients compared
with 190 controls (Fig. 3). Again, we detected no signiﬁcant
difference between cases and controls in the LINE1 assay or
the ATM CpG island. The LINE1 assay did, however, show
inter-individual variability with genome-wide methylation
values ranging from the lowest individual at 48% to the
highest at 74% (median 56%). We did detect a signiﬁcant
increase in methylation of ATMmvp2b in the bilateral breast
cancer patients (range 72.8–98.4%, mean 91.4%) compared
with control individuals (range 53–98%, mean 89.8%) (P ¼
0.001686, Wilcoxon rank sum test) (Supplementary Material,
Fig. S3). We have used an inter-quartile analysis of the ATM
mvp2b methylation data to reveal a signiﬁcant increase in
methylation in cases in the highest quartile (P ¼ 0.0011
using x
2 test), which is associated with a 3-fold increased
risk of breast cancer (odds ratio—OR 3.20, 95% CI 1.78–
5.86, P ¼ 0.000083), compared with the lowest quartile
(Table 1). We have analysed these data to identify whether
the methylation status of this locus is associated with any phe-
notypic characteristics. We have investigated the age at blood
draw (median 6.6 years after second diagnosis), age at ﬁrst and
second diagnoses and the time between diagnoses (Table 2).
There was no association between the methylation level and
tumour morphology, age at ﬁrst full-term pregnancy, age at
menarche, menopausal status, body mass index, weight,
parity and the number of affected ﬁrst-degree relatives (data
not shown). Only the age and the age of diagnoses in the
breast cancer patients were signiﬁcantly associated with the
methylation status (adjusted for multiple testing, P ¼
0.01035). Interestingly, even though the controls were age-
matched with patients, age was not correlated with the methyl-
ation status in the controls (r ¼ 20.1077, P ¼ 0.07), only in
the cases at blood draw (r ¼ 0.242, P ¼ 0.0004), at ﬁrst diag-
nosis (r ¼ 0.189, P ¼ 0.0045) and at second diagnosis (r ¼
0.251, P ¼ 0.0002) (Supplementary Material, Fig. S4).
It is well deﬁned that different tissues show differential
methylation particularly between different peripheral blood
cell types (CD4þ and CD8þ T cells compared with B
cells) (15). Therefore, the small effect (increase in methylation
at ATM mvp2b) in patients compared with controls could be
Figure 1. Methylation microarray analysis of 17 genes reveals methylation
variability in repetitive elements. (A) The distance from each of the MVP to
the nearest repetitive element was calculated for each of the 181 distinct
MVPs revealing 44% of peaks within 100 bp of the nearest repetitive
element. Random placement of 181 simulated MVP peaks reveals a distri-
bution containing only 26% of peaks within 100 bp of the nearest repetitive
element. Kolmogorov–Smirnov test was used to determine the signiﬁcance
of the difference in distribution. (B) The smoothed average of MATScores
(+2 SD in red) for genes aligned at the TSS reveals periodic increase in
methylation variability across the ﬁrst 10 kb (of genes .10 kb) or across
the ﬁrst 5 kb (of shorter genes, median 4.5 kb).
1334 Human Molecular Genetics, 2009, Vol. 18, No. 7Figure 2. Investigation of ATM gene methylation. (A) Methylation microarray data for the ATM gene locus. Seven methylation variable peaks were detected
across the tiled region surrounding the ATM gene. Data are presented as a custom WIG ﬁle track on the UCSC genome browser. (B) Pair-wise comparison of
ATM mvp2a methylation reveals increased methylation in 5/14 bilateral breast cancer patients (blue) compared with matched controls (yellow). Methylation of
six CpG dinucleotides within the repetitive element mvp2a was determined by pyrosequencing. Pair-wise Wilcoxon signed rank sum test was used to determine
statistical signiﬁcance (# indicates P , 0.05). (C) DNA methylation analysis of MVPs reveals signiﬁcant variability detected within the ATM gene. LINE 1 assay
shows no signiﬁcant differences in methylation of LINE1 repetitive elements in peripheral blood DNA of cases (blue) compared with controls (yellow). Methyl-
ation variability was detected in mvp1b, mvp2a, mvp2b, mvp3 and mvp4. Box and whisker plots represent median (centre line), inter-quartile range (box) and
95th percentiles (whisker), and samples outwith this range are represented as points.
Human Molecular Genetics, 2009, Vol. 18, No. 7 1335Figure 3. Methylation of LINE1, ATM CpG island, mvp2a and mvp2b in 190 bilateral breast cancer cases compared with 190 controls. (A) Schematic of the
genomic location of the ATM CpG island (CGI) at the TSS and at mvp2a and mvp2b within the second intron of ATM. (B) Pyrosequencing-based methylation
analysis of 190 bilateral breast cancer cases compared with 190 matched controls reveals no methylation in the promoter CpG island and signiﬁcant inter-
individual methylation variability in the intronic mvp2a and mvp2b. Signiﬁcant hypermethylation of mvp2b is detected in bilateral breast cancer cases com-
pared with controls (P ¼ 0.0017, Wilcoxon signed rank sum test). Box and whisker plots represent median (centre line), inter-quartile range (box) and 95th
percentiles (whisker), and samples outwith this range are represented as points. (C) Kernel density plot of methylation values in cases (solid line) compared
with controls (dotted lines) showing overlapping distributions for LINE1, ATM CpG island and ATM mvp2a and a skewed distribution of methylation at ATM
mvp2b in the cases.
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the heterogeneous peripheral blood cell population. We have
addressed this question by isolation of B cells, T cells and
monocytes from peripheral blood mononuclear cells
(PBMCs) from two healthy controls and investigating the
methylation status of this locus. We show that the methylation
of ATMmvp2b does not show cell-speciﬁc methylation differ-
ences between these three blood cell fractions, and all frac-
tions have similar methylation levels to the whole PBMCs
(Supplementary Material, Fig. S5).
In order to investigate the relationship between methylation
at ATM mvp2b and expression of ATM, we screened a large
panel of cancer cell lines and observed a similar methylation
range as seen in peripheral blood (77–99%); however, the dis-
tribution of methylation percentages is signiﬁcantly higher in
the cancer cell lines than in the peripheral blood DNA of
the patients and controls (P , 1e–14, Wilcoxon signed rank
test) (Fig. 4A). We performed quantitative RT–PCR for
ATM expression in ﬁve breast cancer cell lines (MCF7,
T47D, SKBR3, MDA-MB-231 and BT549) and analysed pre-
existing gene expression data for 18 mesenchymal tumour cell
lines (16) (Fig. 4B and C). In both cases, we observed a cor-
relation between the methylation of the intragenic repetitive
element and expression of ATM (Spearmans rho 20.9 and
20.33, respectively).
DISCUSSION
This project is the ﬁrst comprehensive DNA methylation study
using high-density tiling arrays to look for methylation vari-
ation in white blood cells of bilateral breast cancer patients
compared with controls. It is well established that identiﬁ-
cation of high-risk patients guiding the use of preventative
treatment such as intensive surveillance (e.g. mammography),
chemoprevention (e.g. tamoxifen) or prophylactic surgery
(e.g. radical mastectomy) can signiﬁcantly reduce the burden
of breast cancer (17). Therefore, all additional tools with
which we can predict a patient’s risk of cancer, such as
DNA methylation markers, would improve our ability to
identify those at high risk. The difﬁculty in ﬁnding genetic
markers of common breast cancer risk has been recently exem-
pliﬁed by a number of extraordinarily large case–control
studies that have identiﬁed only minor increases in breast
cancer risk (18,19). The overall goal of this current study
was to screen candidate genes for epigenetic differences in
peripheral blood DNA to identify markers of common breast
cancer risk. We believe that DNA methylation markers
could be more informative, as they are more stable than
other candidate biomarkers such as RNA or protein-based
markers, and can act as a surrogate for environmental
exposures (20). The extent to which epigenetic markers can
be used for risk assessment is yet to be fully explored.
‘Gene body methylation’ is a recent term describing the
DNA methylation that occurs throughout the gene from the
TSS, through exons and introns, to the 30 untranslated region
(21–23). In Arabidopsis, the level of gene-body methylation
has been linked to the level of gene transcription such that
gene-body methylation was absent in genes that were not tran-
scribed, was low in genes that were transcribed at low levels,
higher levels of methylation in the highest transcribed genes
but even higher methylation levels in genes that had inter-
mediate levels of transcription (22). Gene-body methylation
is also more associated with genes on the active X chromo-
some rather than on the inactive X-chromosome (21). The
association with the transcription of individual genes and
gene-body methylation has not yet been investigated in
cancer. We have recently suggested that gene-body methyl-
ation in the human genome may be associated with intragenic
repetitive elements and that altered methylation in the gene-
Table 1. Inter-quartile analysis of ATM mvp2b methylation reveals increased risk of breast cancer in the highest quartile
ATM mvp2b Control (n ¼ 189) Case (n ¼ 190) x
2 OR 95% CI P-value P-trend
Q4 91.5–98.4% 32 63 3.20 1.78–5.86 0.000083 0.00032
Q3 88.6–91.5% 48 44 1.44 0.81–2.58 0.215
Q2 88.6–91.5% 50 47 1.60 0.90–2.87 0.108
Q1 53.0–88.6% 59 36 0.0011 1
Table 2. Association between methylation of ATM mvp2b and phenotypic data from the bilateral breast cancer patients and controls reveals an association
between methylation and age in cases but not in controls
Cases, median
(range)
Cases, P-value
a Cases,
P-adjusted
b
Controls, median
(range)
Controls,
P-value
a
Controls,
P-adjusted
b
Age at blood draw 62.8 (37.5–79.6) 0.00109   0.01035   62.8 (37.1–79.4) 0.106 0.4028
Age at ﬁrst diagnosis 47 (26–64) 0.0145   0.0918 NA NA NA
Age at second diagnosis 56 (26–70) 0.000487   0.0093   NA NA NA
Time between
diagnoses
6 years (0–26) 0.177 0.4204 NA NA NA
NA, not applicable.
aLinear model regression.
bFDR corrected for multiple testing.
  Signiﬁes signiﬁcant association (P , 0.05).
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scription (24). In the present study, we show for the ﬁrst
time that the methylation of one intragenic repetitive
element inversely correlates with the expression of the gene
which supports this hypothesis. Although there are numerous
examples in the literature showing that active genes have
more gene-body methylation levels than inactive genes, all
of these studies compare the gene body methylation levels
of one gene with another and compare the expression levels
(22). These studies make a distinction between ‘On’
expression and gene-body methylation compared with ‘Off’
expression and no gene-body methylation. We suggest from
our data that the level of gene-body methylation may be mod-
ulating or ﬁne-tuning the level of expression of the active
genes. To date, there has been no report looking at the
subtle differences in gene-body methylation across samples
and associating that with the expression of the same gene in
those samples. Therefore, our study is the ﬁrst report of an
association between different levels of gene-body methylation
and expression of the same gene.
How gene-body methylation may alter the gene expression,
or alternatively how expression level may affect the
methylation level, is still not clear. The mvp within ATM
that we have identiﬁed could be a reporter of a more extended
regulatory epigenetic proﬁle at ATM, similar to a tag SNP for a
region of linkage disequilibrium in DNA sequence variation.
Alternatively, this region could be involved in the regulation
of unannotated non-coding transcript(s) or antisense tran-
scripts that regulate the sense gene (22). Recent reports have
shown a high level of antisense transcription throughout the
genome which could be involved in gene regulation, which
suggests new levels of understanding of the process of tran-
scriptional regulation (25,26).
Our study of the breast cancer susceptibility genes has pro-
vided evidence that the regions of inter-individual methylation
variability are located within repetitive elements, particularly
SINEs (Alu sequences), and that the variability is highest at
1 kb downstream of the TSSs and increases periodically
along the gene. We interpret this increased variability as the
point in the genome where the methylation along the chroma-
tin is changing from unmethylated at the promoters to fully
methylated in the gene-body. We have identiﬁed one repetitive
element, ATM mvp2b, which is signiﬁcantly more methylated
in the peripheral blood DNA of women affected with bilateral
breast cancer compared with matched control individuals. On
its own, this is not sufﬁcient to be considered a potential diag-
nostic test, as there is considerable overlap between cases and
controls and the receiver operating curve area under the curve
Figure 4. Correlation between methylation of ATM mvp2b and expression of ATM in cancer cell lines. (A) Methylation analysis in 62 cancer cell lines reveals a
similar range of methylation as in PBMCs of breast cancer patients (77–99%); however, the distribution is skewed towards increased methylation in the cancer
cell lines (green). Methylation distributions of breast cancer patients (red) and controls (black) are shown for comparison. (B) ATM expression was determined
by qRT–PCR in the ﬁve breast cancer cell lines and by gene expression microarray data (C) for a panel of sarcoma cell lines. Error bars represent SEM from
triplicate qRT–PCR experiments. Correlation between methylation and expression is shown using Spearmans rank correlation coefﬁcient.
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However, this may improve in combination with similar
markers from the other genes that we have identiﬁed, if such
markers provide an additive effect. Interestingly, not all
genes showed signs of inter-individual methylation variability.
For some of the genes, this could be explained by the short
length (e.g. SFN, GSTP1 and HIC1); however, this is not the
case for other longer genes which could represent genes
with conserved methylation patterns (e.g. BRCA1, BRCA2
and TP53) compared with other long genes that show high
levels of methylation variability (e.g. CDH13).
The ataxia telangiectasia (A-T) mutated (ATM) gene is
considered a breast cancer susceptibility gene, as female
heterozygotes from A-T families have an increased risk of
breast cancer and a number of breast cancer families have
been identiﬁed with germline ATM mutations (27,28).
Although one small study by Vo et al. identiﬁed increased
ATM promoter methylation associated with decreased
expression in locally advanced sporadic breast cancers,
numerous other reports suggest no evidence of promoter
methylation of this gene in breast cancers (29–32). One
ﬁnding that is consistent is that ATM expression is often
reduced in breast tumours (31–34). This could be explained
by genetic haploinsufﬁciency (35); however, our data in
peripheral blood DNA and cancer cell lines suggest a novel
mechanism of decreased expression mediated by aberrant gene-
body methylation, which warrants further investigation in
tumour tissues. We propose that if normal tissues of the individ-
ual, including mammary epithelial cells, express lower levels of
ATM owing to aberrantly increased gene-body methylation, then
t h e s ei n d i v i d u a l sm a yb em o r es u s c e p t i b l et oD N Am u t a t i o n si n
those cells.
The biggest risk factor for breast cancer and indeed most
cancers is increasing age. The incidence of breast cancer in
women doubles for every 10 years until menopause with a
relative risk of .10-fold (36). An association between DNA
methylation and increasing age has also been reported, for
example increased DNA methylation variability in older
twins compared with younger twins and increasing variability
with increasing age in familial clusters (37,38). However, we
have found that the association between the level of methyl-
ation at ATM mvp2b and increasing age is only associated
in the bilateral breast cancer patients and not in controls.
This suggests that the relationship between age and DNA
methylation may be more dependent on the phenotype of the
individuals, in this case cancer, and may be due to other pre-
disposing environmental exposures that accumulate with age.
One of the confounding factors which we cannot rule out in
this study is the long-term effects of previous therapy in the
patients that are not present in the controls. Future studies
will need to investigate peripheral blood samples taken
before the initiation of treatment preferably in prospectively
collected cohort studies to rule out this possibility. However,
if therapy accounted for an overall difference in genome-wide
DNA methylation, the LINE1 assay for genome-wide methyl-
ation and the other unique sites tested (ATM mvp2a) would
have detected this, which it did not. Another confounding
factor is the effect of tissue-speciﬁc methylation. Although
we have shown that in two healthy controls there is no evi-
dence for cell-type-speciﬁc methylation of this locus, we
cannot rule out this possibility in cancer patients. Therefore,
this needs to be addressed in cancer patients.
In summary, we have shown that inter-individual variability
in gene-body methylation is associated with repetitive elements
and that it is possible to identify regions of signiﬁcant differ-
ences between bilateral breast cancer patients and controls
that may be useful as additional surrogate markers for breast
cancer risk. This research also demonstrates the correlation
between the level of gene-body methylation and mRNA level
of a single gene and highlights the potential for gene-body epi-
genetic regulation of gene transcription. Finally, this work also
supports the need to interrogate whole epigenomes, including
repetitive elements, using tiling arrays or unbiased next-
generation sequencing approaches to investigate the full comp-
lement of methylation variability across the genome.
MATERIALS AND METHODS
Clinical sample
For the microarray analysis, peripheral blood DNA samples
from 14 women with bilateral breast cancer were compared
with the DNA samples from 14 age- and ethnicity-matched
controls. The cases were selected by being (i) BRCA1 and
BRCA2 mutation negative, conﬁrmed clinically; (ii) metachro-
nous tumours (separate sites) (iii) and those meet the bilateral
case criteria set by Chaudary et al. (39), namely (a) subsequent
tumour contains in situ component; (b) distinct histological
types; (c) subsequent tumour has greater degree of differen-
tiation; (d) no evidence of metastatic spread from ipsilateral
tumour. These samples were collected with ethics approval
from the Institute for Womens Health, Toronto, Canada. Per-
ipheral blood DNA samples from a second set of 190 bilateral
cases and 190 controls were obtained from the British Breast
Cancer study (40,41). Bilateral breast cancer patients were
ascertained through the English and Scottish cancer registries,
controls were friends or non-blood relatives of breast cancer
patients. Controls were age-matched to patients at the age at
blood draw (within +2 months) and all patients and controls
were Caucasians resident in the UK. Written informed consent
was obtained from all participants, and the study was approved
by the South East Multicentre Research Ethics Committee.
DNA methylation proﬁling using microarrays
A custom oligonucleotide tiling array was designed to target
the testable genomic regions (plus 100 kb ﬂanking sequence)
of genes, including breast cancer susceptibility genes BRCA1
(82 kb), BRCA2 (86 kb), CHEK2 (57 kb) and ATM (143 kb)
along with other genes that are known to be commonly
methylated in breast cancer, including ESR1 (296 kb), SFN
(1.3 kb), CDKN2A (27 kb), TP53 (19 kb), GSTP1 (2.8 kb),
CDH1 (96 kb), CDH13 (1169 kb), HIC1 (4.0 kb), PGR
(92 kb), SFRP1 (47 kb), MLH1 (57 kb), RARB (97 kb),
HSD17B4 (90 kb). Arrays were designed by and performed
by Nimblegen Inc. Speciﬁed regions were from UCSC
HG17 with overlapping 50mer probes every 21 bp excluding
repeat masked regions, and the probe set was replicated four
times on the chip and averaged data were used for analysis.
In addition to the 17 targeted genes, we also captured 26
Human Molecular Genetics, 2009, Vol. 18, No. 7 1339genes and 12 partial genes which were peripherally targeted in
the ﬂanking regions by these tiling arrays (Supplementary
Material, Table S1).
The general principle of these DNA methylation arrays con-
sists of hybridization of the unmethylated fraction of genomic
DNA to the microarray containing oligonucleotides that rep-
resent the genomic region of interest. We performed the
enrichment as described previously (42). Brieﬂy, we used a
cocktail of three methylation-sensitive enzymes (HpaII, AciI
and Hin6I) to digest individuals genomic DNA and used
ligation-mediated PCR to amplify products which were
cleaned using Qiagen PCR cleanup kit (Qiagen, Canada),
labelled with either Cy3 or Cy5 dyes and co-hybridized in
matched pairs to the custom array. Hybridization intensity cor-
relates with the DNA methylation status at the genomic locus
homologous to each oligonucleotide on the array. MA2C was
used for normalization, peak detection (using a cut-off of P ,
0.001) and generation of MATScores for each probe (43).
Pyrosequencing
DNA samples were bisulphite-converted using EZ-96 DNA
Methylation-Gold kit (Zymo Research, Orange, CA, USA)
following the manufacturers protocol. Pyrosequencing of
LINE1 elements was performed using the LINE1 assay
(Biotage, Hertford, UK). All other pyrosequencing assays
were designed using the PyroQ assay design software
(primers in Supplementary Material, Table S3). All pyrose-
quencing assays for repetitive elements included at least one
primer in a unique sequence outside of the repeat and followed
by a unique nested primer pair for some amplicons to ensure
speciﬁc ampliﬁcation. A common tag was placed on either
the forward or the reverse primer (depending on the strand
to be sequenced), and a common universal biotinylated
primer was used for all reactions as described previously
(44). PCR was performed as described previously and
cycling conditions included denaturation at 958C for 4 min,
followed by 10 cycles of 948C for 15 s, touchdown from
60–508C( 21 degree/cycle) for 15 s and 728C for 20 s, fol-
lowed by a further 30 cycles at 508C annealing temperature.
The second PCR used 2 ml of a 1:10 dilution of the ﬁrst
PCR as template and the same cycling conditions (13). All
products were conﬁrmed to be single bands by agarose gel
electrophoresis. Methylation values were calculated as an
average of all CpG sites within each assay as determined by
the Pyro Q-CpG Software (Biotage, Uppsala, Sweden).
Blood cell fractionation
Peripheral blood was collected from two healthy female
donors with informed consent. PBMCs were isolated using a
standard Ficoll-paque protocol, and blood cell fractions were
isolated using antibody-coated magnetic microbeads and
MACS MS separation columns (cat: 130-042-201) following
the manufacturers protocol (Miltenyi Biotech, Surrey, UK).
Brieﬂy, 5–10 million PBMCs were incubated with each of
the antibody-coated beads for B-cells (CD19, cat:
130-050-301), T-cells (CD2, cat: 130-091-114) or monocytes
(CD14, cat: 130-050-201). Genomic DNA was extracted
from whole PBMCs and each cell-speciﬁc population. Bisul-
phite conversion and pyrosequencing were performed as
described.
Cancer cell lines
DNA was extracted from 62 cell lines from brain (n ¼ 7),
breast (n ¼ 5), colon (n ¼ 5), leukaemia (n ¼ 5), lymphoma
(n ¼ 9), sarcoma (n ¼ 15) and others (n ¼ 16). A full list of
cell line names is included in Supplementary Material,
Table S4. Bisulphite conversion and pyrosequencing were per-
formed as described.
Quantitative RT–PCR
Quantitative RT–PCR was performed for ATM using an
Eppendorf Mastercycler with the following primer pairs:
ATM_F (50-tgctcatacagcaggccata-30) with ATM_R (50-aa
ggctgaatgaaagggtaattc-30) and GAPDH_F (50-ggagtcaacgga
tttggtcgta-30) with GAPDH_R (50-ggcaacaatatccactttaccaga
gt-30). The reaction mix contained 1  SYBR green master
mix (Applied Biosystems, Foster City, CA, USA) and
0.5 mM of each forward and reverse primers in a volume of
30 ml. PCR cycling consisted of 958C for 10 min, then 40
cycles of 958C for 30 s, 608C for 60 s, followed by a meltcurve
analysis. Fold-change in expression was calculated by DDCt
normalized to GAPDH for each sample and normalizing ea
ch of the cell lines to the cell line SKBR3.
Statistical analysis
The majority of statistical analysis in this study was performed
using various R packages as described earlier. The simulated
peak distributions were determined by randomly placing
single peaks across the same tiled region and calculating the
distances to the real repetitive elements and repeating 10 000
times. Kolmogorov–Smirnov test was used to test the signiﬁ-
cance of the difference in distributions (ks.test). We used Wil-
coxon signed rank test for the analysis of methylation
percentages obtained by pyrosequencing (wilcox.test). We
performed further analysis for ATM mvp2a to conﬁrm the sig-
niﬁcance of this difference using 1000 randomized simulations
of the test statistic (W, from the Wilcoxon rank sum test) to
calculate the real P-value of the observed test statistic. We
used either generalized linear model (glm) regression or logis-
tic regression analysis (lm) for further analysis of ATM
MVP2b to assess the associations with phenotypic data. Inter-
quartile analysis was performed by calculating the quartiles
from all of the data (quantile) and counting the number of
cases or controls in each quartile. We then used the x
2 test
(chisq.test), odds ratio (oddsratio) and Cochran–Armitage
trend test (independence_test).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
1340 Human Molecular Genetics, 2009, Vol. 18, No. 7ACKNOWLEDGEMENTS
The authors would like to thank Dr Jon Mill for a critical
review of the manuscript and Dr Matthew Trotter for
additional bioinformatic assistance.
Conﬂict of Interest statement. None declared.
FUNDING
This work was funded in part by a pilot study grant from the
Canadian Cancer Etiology Research Network (CCERN) to
A.P., S.N. and J.M.F. and a grant from the University
College London Hospital Charities to J.M.F. J.M.F. was
funded in part by Cellcentric Ltd and by Cancer Research
UK. The British Breast Cancer study is funded by Cancer
Research UK and Breakthrough Breast Cancer Research
Centre. We acknowledge NHS funding to the NIHR Biomedi-
cal Research Centre. Funding to pay the Open Access charge
was provided by a grant from the University College London
Hospital Charities.
REFERENCES
1. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A.,
Feuer, E.J. and Thun, M.J. (2005) Cancer statistics, 2005. CA Cancer
J. Clin., 55, 10–30.
2. Smith, P., McGuffog, L., Easton, D.F., Mann, G.J., Pupo, G.M., Newman,
B., Chenevix-Trench, G., Szabo, C., Southey, M., Renard, H. et al. (2006)
A genome wide linkage search for breast cancer susceptibility genes.
Genes, Chromosomes Cancer, 45, 646–655.
3. Weitzel, J.N., Robson, M., Pasini, B., Manoukian, S., Stoppa-Lyonnet, D.,
Lynch, H.T., McLennan, J., Foulkes, W.D., Wagner, T., Tung, N. et al.
(2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer
Epidemiol. Biomarkers Prev., 14, 1534–1538.
4. Cui, H., Cruz-Correa, M., Giardiello, F.M., Hutcheon, D.F., Kafonek,
D.R., Brandenburg, S., Wu, Y., He, X., Powe, N.R. and Feinberg, A.P.
(2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer
risk. Science, 299, 1753–1755.
5. Suter, C.M., Martin, D.I. and Ward, R.L. (2004) Germline epimutation of
MLH1 in individuals with multiple cancers. Nat. Genet., 36, 497–501.
6. Baylin, S. and Bestor, T.H. (2002) Altered methylation patterns in cancer
cell genomes: cause or consequence? Cancer Cell, 1, 299–305.
7. Kouzarides, T. (2007) Chromatin modiﬁcations and their function. Cell,
128, 693–705.
8. Feinberg, A.P., Ohlsson, R. and Henikoff, S. (2006) The epigenetic
progenitor origin of human cancer. Nat. Rev. Genet., 7, 21–33.
9. Richards, E.J. (2006) Inherited epigenetic variation—revisiting soft
inheritance. Nat. Rev. Genet., 7, 395–401.
10. Morgan, D.K. and Whitelaw, E. (2008) The case for transgenerational
epigenetic inheritance in humans. Mamm. Genome, 19, 394–397.
11. Ito, Y., Koessler, T., Ibrahim, A.E., Rai, S., Vowler, S.L., Abu-Amero, S.,
Silva, A.L., Maia, A.T., Huddleston, J.E., Uribe-Lewis, S. et al. (2008)
Somatically acquired hypomethylation of IGF2 in breast and colorectal
cancer. Hum. Mol. Genet., 17, 2633–2643.
12. Reik, W., Dean, W. and Walter, J. (2001) Epigenetic reprogramming in
mammalian development. Science, 293, 1089–1093.
13. Flanagan, J.M., Popendikyte, V., Pozdniakovaite, N., Sobolev, M.,
Assadzadeh, A., Schumacher, A., Zangeneh, M., Lau, L., Virtanen, C.,
Wang, S.C. et al. (2006) Intra- and interindividual epigenetic variation in
human germ cells. Am. J. Hum. Genet., 79, 67–84.
14. Ordway, J.M., Budiman, M.A., Korshunova, Y., Maloney, R.K., Bedell,
J.A., Citek, R.W., Bacher, B., Peterson, S., Rohlﬁng, T., Hall, J. et al.
(2007) Identiﬁcation of novel high-frequency DNA methylation changes
in breast cancer. PLoS ONE, 2, e1314.
15. Rakyan, V.K., Down, T.A., Thorne, N.P., Flicek, P., Kulesha, E., Graf, S.,
Tomazou, E.M., Backdahl, L., Johnson, N., Herberth, M. et al. (2008) An
integrated resource for genome-wide identiﬁcation and analysis of human
tissue-speciﬁc differentially methylated regions (tDMRs). Genome Res.,
18, 1518–1529.
16. Henderson, S.R., Guiliano, D., Presneau, N., McLean, S., Frow, R.,
Vujovic, S., Anderson, J., Sebire, N., Whelan, J., Athanasou, N. et al.
(2005) A molecular map of mesenchymal tumors. Genome Biol., 6, R76.
17. Sakorafas, G.H. (2003) The management of women at high risk for the
development of breast cancer: risk estimation and preventative strategies.
Cancer Treat. Rev., 29, 79–89.
18. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D.,
Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R. et al.
(2007) Genome-wide association study identiﬁes novel breast cancer
susceptibility loci. Nature, 447, 1087–1093.
19. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J.,
Gudjonsson,S.A.,Masson,G.,Jakobsdottir,M.,Thorlacius,S.,Helgason,A.
et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer
susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 39,
865–869.
20. Li, S., Hursting, S.D., Davis, B.J., McLachlan, J.A. and Barrett, J.C.
(2003) Environmental exposure, DNA methylation, and gene regulation:
lessons from diethylstilbesterol-induced cancers. Ann. NY Acad. Sci., 983,
161–169.
21. Hellman, A. and Chess, A. (2007) Gene body-speciﬁc methylation on the
active X chromosome. Science, 315, 1141–1143.
22. Zilberman, D., Gehring, M., Tran, R.K., Ballinger, T. and Henikoff, S.
(2007) Genome-wide analysis of Arabidopsis thaliana DNA methylation
uncovers an interdependence between methylation and transcription. Nat.
Genet., 39, 61–69.
23. Suzuki, M.M. and Bird, A. (2008) DNA methylation landscapes:
provocative insights from epigenomics. Nat. Rev. Genet., 9, 465–476.
24. Flanagan, J.M. and Wild, L. (2007) An epigenetic role for noncoding
RNAs and intragenic DNA methylation. Genome Biol., 8, 307.
25. Core, L.J., Waterfall, J.J. and Lis, J.T. (2008) Nascent RNA sequencing
reveals widespread pausing and divergent initiation at human promoters.
Science, 322, 1845–1848.
26. He, Y., Vogelstein, B., Velculescu, V.E., Papadopoulos, N. and Kinzler,
K.W. (2008) The antisense transcriptomes of human cells. Science, 322,
1855–1857.
27. Chenevix-Trench, G., Spurdle, A.B., Gatei, M., Kelly, H., Marsh, A.,
Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M.A. et al.
(2002) Dominant negative ATM mutations in breast cancer families.
J. Natl. Cancer Inst., 94, 205–215.
28. Swift, M., Morrell, D., Massey, R.B. and Chase, C.L. (1991) Incidence of
cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med.,
325, 1831–1836.
29. Allinen, M., Peri, L., Kujala, S., Lahti-Domenici, J., Outila, K.,
Karppinen, S.M., Launonen, V. and Winqvist, R. (2002) Analysis of
11q21–24 loss of heterozygosity candidate target genes in breast cancer:
indications of TSLC1 promoter hypermethylation. Genes, Chromosomes
Cancer, 34, 384–389.
30. Kontorovich, T., Cohen, Y., Nir, U. and Friedman, E. (2008) Promoter
methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative
cancer risk modiﬁers in Jewish BRCA1/BRCA2 mutation carriers. Breast
Cancer Res. Treat. July 19 [Epub ahead of print].
31. Treilleux, I., Chapot, B., Goddard, S., Pisani, P., Angele, S. and Hall, J.
(2007) The molecular causes of low ATM protein expression in breast
carcinoma; promoter methylation and levels of the catalytic subunit of
DNA-dependent protein kinase. Histopathology, 51, 63–69.
32. Vo, Q.N., Kim, W.J., Cvitanovic, L., Boudreau, D.A., Ginzinger, D.G.
and Brown, K.D. (2004) The ATM gene is a target for epigenetic silencing
in locally advanced breast cancer. Oncogene, 23, 9432–9437.
33. Tommiska, J., Bartkova, J., Heinonen, M., Hautala, L., Kilpivaara, O.,
Eerola, H., Aittomaki, K., Hofstetter, B., Lukas, J., von Smitten, K. et al.
(2008) The DNA damage signalling kinase ATM is aberrantly reduced or
lost in BRCA1/BRCA2-deﬁcient and ER/PR/ERBB2-triple-negative
breast cancer. Oncogene, 27, 2501–2506.
34. Ye, C., Cai, Q., Dai, Q., Shu, X.O., Shin, A., Gao, Y.T. and Zheng, W.
(2007) Expression patterns of the ATM gene in mammary tissues and
their associations with breast cancer survival. Cancer, 109, 1729–1735.
35. Lu, S., Shen, K., Wang, Y., Santner, S.J., Chen, J., Brooks, S.C. and
Wang, Y.A. (2006) Atm-haploinsufﬁciency enhances susceptibility to
carcinogen-induced mammary tumors. Carcinogenesis, 27, 848–855.
Human Molecular Genetics, 2009, Vol. 18, No. 7 134136. McPherson, K., Steel, C.M. and Dixon, J.M. (2000) ABC of breast
diseases. Breast cancer-epidemiology, risk factors, and genetics.
Br. Med. J. (Clin. Res. Ed.), 321, 624–628.
37. Bjornsson, H.T., Sigurdsson, M.I., Fallin, M.D., Irizarry, R.A., Aspelund,
T., Cui, H., Yu, W., Rongione, M.A., Ekstrom, T.J., Harris, T.B. et al.
(2008) Intra-individual change over time in DNA methylation with
familial clustering. JAMA, 299, 2877–2883.
38. Fraga, M.F., Ballestar, E., Paz, M.F., Ropero, S., Setien, F., Ballestar,
M.L., Heine-Suner, D., Cigudosa, J.C., Urioste, M., Benitez, J. et al.
(2005) Epigenetic differences arise during the lifetime of monozygotic
twins. Proc. Natl Acad. Sci. USA, 102, 10604–10609.
39. Chaudary, M.A., Gravelle, I.H., Bulstrode, J.C., Wang, D.Y., Bulbrook,
R.D.,Millis,R.R.andHayward,J.L.(1983)Breastparenchymal patternsin
women with bilateral primary breast cancer. Br. J. Radiol., 56, 703–706.
40. Fletcher, O., Johnson, N., Gibson, L., Coupland, B., Fraser, A., Leonard,
A., dos Santos Silva, I., Ashworth, A., Houlston, R. and Peto, J. (2008)
Association of genetic variants at 8q24 with breast cancer risk. Cancer
Epidemiol. Biomarkers Prev., 17, 702–705.
41. Johnson, N., Fletcher, O., Naceur-Lombardelli, C., dos Santos Silva, I.,
Ashworth, A. and Peto, J. (2005) Interaction between CHEK2 1100delC
and other low-penetrance breast-cancer susceptibility genes: a familial
study. Lancet, 366, 1554–1557.
42. Schumacher, A., Kapranov, P., Kaminsky, Z., Flanagan, J., Assadzadeh,
A., Yau, P., Virtanen, C., Winegarden, N., Cheng, J., Gingeras, T. et al.
(2006) Microarray-based DNA methylation proﬁling: technology and
applications. Nucleic Acids Res., 34, 528–542.
43. Song, J.S., Johnson, W.E., Zhu, X., Zhang, X., Li, W., Manrai, A.K., Liu,
J.S., Chen, R. and Liu, X.S. (2007) Model-based analysis of two-color
arrays (MA2C). Genome Biol., 8, R178.
44. Royo, J.L., Hidalgo, M. and Ruiz, A. (2007) Pyrosequencing protocol
using a universal biotinylated primer for mutation detection and SNP
genotyping. Nat. Protoc., 2, 1734–1739.
1342 Human Molecular Genetics, 2009, Vol. 18, No. 7